Pfizer and AstraZeneca top annual pharma future-readiness rankings

[See Less/Adobe Stock]

As 2023 draws to a close, the pharma industry finds itself at an inflection point. On the one hand, stubbornly high inflation rates, a dearth of talent, supply chain hurdles, and a more challenging regulatory climate threaten profitability. But on the other, the rapid advances in areas ranging from cell and gene therapy and IT technology offer new opportunities for efficiency gains and innovation.

Pfizer, AstraZeneca and Lilly come out on top in future-readiness

Against that backdrop, Pfizer, AstraZeneca and Lilly round out the top three rankings in terms of future-readiness, according to an analysis from IMD. In its annual ranking, Pfizer advanced from second to first place, Eli Lilly moved up from seventh to third place, and Novo Nordisk rose from 13th to seventh. While Pfizer has had something of a rough year, missing its revenue projections as demand for Paxlovid and Corminaty slides, …

Read more
  • 0